Skip to main content

Advertisement

SpringerLink
Log in

miR-548 predicts clinical prognosis and functions as a tumor promoter in gastric cancer

  • Original Article
  • Published:
Clinical and Experimental Medicine Aims and scope Submit manuscript

Abstract

Numerous pieces of evidence have demonstrated the functional role of miR-548 in various cancers. The expression and function of miR-548 in gastric cancer were investigated in the present study. A total of 123 gastric cancer patients were included and provided paired gastric cancer tissues and matched normal tissues. RT-qPCR was used to detect the expression of miR-548. CCK8 assay was used to evaluate cell proliferation, and Transwell assay was applied to assess cell migration and invasion. The clinical significance of miR-548 was estimated by a series of statistical analyses. miR-548 was found to be upregulated in gastric cancer, which was associated with the lymph node metastasis and TNM stage of patients. Patients with relatively high miR-548 expression possessed bad survival. miR-548 was identified as a prognostic indicator of gastric cancer. miR-548 was also found to promote the proliferation, migration, and invasion of gastric cancer. Upregulated miR-548 was involved in the progression of gastric cancer and predicted the prognosis of patients. Inhibition of miR-548 might be a novel therapeutic strategy for gastric cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Availability of data and materials

Where appropriate, the corresponding author may provide data.

References

  1. Feng F, Liu J, Wang F, et al. Prognostic value of differentiation status in gastric cancer. BMC Cancer. 2018;18(1):865.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Nienhuser H, Schmidt T. Angiogenesis and anti-angiogenic therapy in gastric cancer. Int J Mol Sci. 2017;19(1):43.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 2014;23(5):700–13.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Liu YJ, Wang GC, Wan XB, et al. Surgical resection for gastric cancer patients with liver metastasis. Zhonghua Zhong Liu Za Zhi. 2017;39(7):532–5.

    CAS  PubMed  Google Scholar 

  5. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med. 2012;4(3):143–59.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Acunzo M, Romano G, Wernicke D, Croce CM. MicroRNA and cancer–a brief overview. Adv Biol Regul. 2015;57:1–9.

    Article  CAS  PubMed  Google Scholar 

  7. Mohr AM, Mott JL. Overview of microRNA biology. Semin Liver Dis. 2015;35(1):3–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. He X, Shu Y. miR-452 promotes the development of gastric cancer via targeting EPB41L3. Pathol Res Pract. 2020;216(1):152725.

    Article  CAS  PubMed  Google Scholar 

  9. Liu D, Hu X, Zhou H, Shi G, Wu J. Identification of aberrantly expressed miRNAs in gastric cancer. Gastroenterol Res Pract. 2014;2014:473817.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Xu Y, Zhong YD, Zhao XX. MiR-548b suppresses proliferative capacity of colorectal cancer by binding WNT2. Eur Rev Med Pharmacol Sci. 2020;24(20):10535–41.

    CAS  PubMed  Google Scholar 

  11. Saffari M, Ghaderian SMH, Omrani MD, Afsharpad M, Shankaie K, Samadaian N. The association of miR-let 7b and miR-548 with PTEN in prostate cancer. Urol J. 2019;16(3):267–73.

    PubMed  Google Scholar 

  12. Yugawa K, Yoshizumi T, Mano Y, et al. Cancer-associated fibroblasts promote hepatocellular carcinoma progression through downregulation of exosomal miR-150-3p. Eur J Surg Oncol. 2021;47(2):384–93.

    Article  PubMed  Google Scholar 

  13. Park S, Eom K, Kim J, et al. MiR-9, miR-21, and miR-155 as potential biomarkers for HPV positive and negative cervical cancer. BMC Cancer. 2017;17(1):658.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Tan PY, Wen LJ, Li HN, Chai SW. MiR-548c-3p inhibits the proliferation, migration and invasion of human breast cancer cell by targeting E2F3. Cytotechnology. 2020;72(5):751–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Wang Z, Wu X, Hou X, et al. miR-548b-3p functions as a tumor suppressor in lung cancer. Lasers Med Sci. 2020;35(4):833–9.

    Article  PubMed  Google Scholar 

  16. Jin M, Lu S, Wu Y, et al. Hsa_circ_0001944 promotes the growth and metastasis in bladder cancer cells by acting as a competitive endogenous RNA for miR-548. J Exp Clin Cancer Res. 2020;39(1):186.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Ni XF, Zhao LH, Li G, et al. MicroRNA-548-3p and MicroRNA-576-5p enhance the migration and invasion of esophageal squamous cell carcinoma cells via NRIP1 down-regulation. Neoplasma. 2018;65(6):881–7.

    Article  CAS  PubMed  Google Scholar 

  18. Ebrahimi Ghahnavieh L, Tabatabaeian H, Ebrahimi Ghahnavieh Z, et al. Fluctuating expression of miR-584 in primary and high-grade gastric cancer. BMC Cancer. 2020;20(1):621.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Wittekind C. The development of the TNM classification of gastric cancer. Pathol Int. 2015;65(8):399–403.

    Article  PubMed  Google Scholar 

  20. Qiu Z, Li H, Wang J, Sun C. miR-146a and miR-146b in the diagnosis and prognosis of papillary thyroid carcinoma. Oncol Rep. 2017;38(5):2735–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Zheng GD, Xu ZY, Hu C, et al. Exosomal miR-590–5p in serum as a biomarker for the diagnosis and prognosis of gastric cancer. Front Mol Biosci. 2021;8:636566.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Amieva M, Peek RM Jr. Pathobiology of helicobacter pylori-induced gastric cancer. Gastroenterology. 2016;150(1):64–78.

    Article  CAS  PubMed  Google Scholar 

  23. Del Rio P, Viani L, Bertocchi E, et al. The prognostic role of tumor size in patients with gastric cancer. Ann Ital Chir. 2017;88:478–84.

    PubMed  Google Scholar 

  24. Christofides A, Papagregoriou G, Dweep H, et al. Evidence for miR-548c-5p regulation of FOXC2 transcription through a distal genomic target site in human podocytes. Cell Mol Life Sci. 2020;77(12):2441–59.

    Article  CAS  PubMed  Google Scholar 

  25. Wang M, Yang M, Deng B. miR-548a-3p weakens the tumorigenesis of colon cancer through targeting TPX2. Cancer Biother Radiopharm 2020

  26. Yang C, Li Q, Chen X, et al. Circular RNA circRGNEF promotes bladder cancer progression via miR-548/KIF2C axis regulation. Aging (Albany NY). 2020;12(8):6865–79.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

There was no funding for this study.

Author information

Authors and Affiliations

  1. Department of Digestive Internal Medicine, Seventh People’s Hospital of Shanghai University of TCM, 358 Gaoqiao Datong Road, Shanghai, 200137, China

    Guoyan Chen, Jingjuan Shang, Minhong Li, Huijun Zhang & Hui Xu

Authors
  1. Guoyan Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jingjuan Shang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Minhong Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Huijun Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hui Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hui Xu.

Ethics declarations

Conflict of interest

The authors have no conflicts of interest to declare.

Ethics approval

This study was approved by the Ethics Committee of Seventh People's Hospital of Shanghai University of TCM.

Consent to participate

All patients had signed informed consent and were followed up for 5 years to track their survival information.

Consent for publication

 Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chen, G., Shang, J., Li, M. et al. miR-548 predicts clinical prognosis and functions as a tumor promoter in gastric cancer. Clin Exp Med 23, 1633–1639 (2023). https://doi.org/10.1007/s10238-022-00870-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10238-022-00870-9

Keywords

Search

Navigation